Bio pet food startup Limpid announced on the 11th that it had attracted a total of 1.5 billion won in investment in a Pre-A investment round that closed in the first half of 2025. Samsung Fire & Marine Insurance-Infobank, Oracle Venture Investment, Kyungpook National University Technology Holdings, CNT Tech, and Korea Credit Guarantee Fund participated in this investment.
Limpid plans to focus the funds it has secured this time on ▲entering the North American market ▲expanding the product line of its general feed brand ‘Trusty Food’ and prescription feed brand ‘Doctor Trusty’ ▲advancing research and development (R&D) based on clinical trials, etc.
Last year, Limpid acquired a freeze-dried pet food manufacturing facility to strengthen production efficiency and quality management systems, and has since expanded its presence in the functional pet food market by launching the freeze-dried prescription feed brand, ‘Doctor Trusty.’
In addition, through cooperation with Kyungpook National University College of Veterinary Medicine, we are promoting the establishment of a clinical trial center dedicated to companion animals, and through our own platform ‘Salad Pet’, we are collecting and analyzing feed intake data to expand into companion animal healthcare services. This vertically integrated structure linking manufacturing-clinical-data platforms is evaluated as Limpid’s differentiated competitiveness.
Limpid has already surpassed its annual sales for the first half of this year and is targeting sales growth of approximately 600% by the end of the year. In the second half of the year, it plans to fully advance into overseas markets by entering major North American e-commerce channels and signing local partnerships.
In addition, we are pursuing a leap forward as a global pet nutrition solutions company by expanding our lineup of functional prescription feed and vegan feed based on alternative meat.
Oracle Venture Investment Managing Director Sang-Hyeon Cho said, “Limpid is a rare pet food company in Korea that has vertically integrated freeze-drying technology, clinical trial capabilities, and a data-based platform,” and “It has a structure that can quickly achieve results in the North American market, so we expect that global scale-up will be possible.”
- See more related articles
You must be logged in to post a comment.